Search

Your search keyword '"Laserna-Mendieta, E. J."' showing total 8 results
Start Over Author "Laserna-Mendieta, E. J."
8 results on '"Laserna-Mendieta, E. J."'

2. Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease

Author

Ryan, F. J., Ahern, A. M., Fitzgerald, R. S., Laserna-Mendieta, E. J., Power, E. M., Clooney, A. G., O’Donoghue, K. W., McMurdie, P. J., Iwai, S., Crits-Christoph, A., Sheehan, D., Moran, C., Flemer, B., Zomer, A. L., Fanning, A., O’Callaghan, J., Walton, J., Temko, A., Stack, W., Jackson, L., Joyce, S. A., Melgar, S., DeSantis, T. Z., Bell, J. T., Shanahan, F., and Claesson, M. J.

Published
2020
Full Text
View/download PDF

4. Esophageal microbiome in active eosinophilic esophagitis and changes induced by different therapies

Author

Asociación Española de Gastroenterología, University of Graz, Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad (España), European Commission, Fundación del Hospital Nacional de Parapléjicos para la Investigación y la Integración (España), Laserna-Mendieta, E. J., FitzGerald, J. A., Arias-Gonzalez, L., Ollala, J. M., Bernardo, David, Claesson, M. J., Lucendo, A. J., Asociación Española de Gastroenterología, University of Graz, Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad (España), European Commission, Fundación del Hospital Nacional de Parapléjicos para la Investigación y la Integración (España), Laserna-Mendieta, E. J., FitzGerald, J. A., Arias-Gonzalez, L., Ollala, J. M., Bernardo, David, Claesson, M. J., and Lucendo, A. J.

Abstract

Eosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory esophageal disease triggered by food antigens. Cumulative evidence supports the implication of microbiota and the innate immune system in the pathogenesis of EoE. Changes in the esophageal microbiome were investigated by applying 16S rRNA gene sequencing on esophageal biopsies of adult patients with active EoE at baseline (n = 30), and after achieving remission with either proton pump inhibitors (PPI, n = 10), swallowed topical corticosteroids (STC, n = 10) or food-elimination diets (FED, n = 10). Ten non-EoE biopsies were also characterized as controls. Compared to controls, no differences in alpha (intra-sample) diversity were found in EoE microbiota overall. However, it decreased significantly among patients who underwent FED. As for beta (inter-sample) diversity, non-EoE controls separated from EoE baseline samples. Post-treatment samples from patients treated with PPI and FED had a more similar microbiota composition, while those receiving STC were closer to controls. Differential testing of microbial relative abundance displayed significant changes for Filifactor, Parvimonas and Porphyromonas genera. Analysis of predicted functions indicated alterations in metabolic pathways and abundance of sulphur-cytochrome oxidoreductases. Our findings demonstrate changes in microbiota associated with EoE, as well as a treatment effect on the microbiome.

Published
2021

5. Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease

Author

Klinische infectiologie en microb. lab., dI&I I&I-4, Ryan, F. J., Ahern, A. M., Fitzgerald, R. S., Laserna-Mendieta, E. J., Power, E. M., Clooney, A. G., O’Donoghue, K. W., McMurdie, P. J., Iwai, S., Crits-Christoph, A., Sheehan, D., Moran, C., Flemer, B., Zomer, A. L., Fanning, A., O’Callaghan, J., Walton, J., Temko, A., Stack, W., Jackson, L., Joyce, S. A., Melgar, S., DeSantis, T. Z., Bell, J. T., Shanahan, F., Claesson, M. J., Klinische infectiologie en microb. lab., dI&I I&I-4, Ryan, F. J., Ahern, A. M., Fitzgerald, R. S., Laserna-Mendieta, E. J., Power, E. M., Clooney, A. G., O’Donoghue, K. W., McMurdie, P. J., Iwai, S., Crits-Christoph, A., Sheehan, D., Moran, C., Flemer, B., Zomer, A. L., Fanning, A., O’Callaghan, J., Walton, J., Temko, A., Stack, W., Jackson, L., Joyce, S. A., Melgar, S., DeSantis, T. Z., Bell, J. T., Shanahan, F., and Claesson, M. J.

Published
2020

6. Single nucleotide polymorphisms in ADAM17, IL23R and SLCO1C1 genes protect against infliximab failure in adults with Crohn's disease.

Author

Laserna-Mendieta EJ, Salvador-Martín S, Arias A, López-Cauce B, Marín-Jiménez I, Menchén LA, Marín-Rubio L, Ontañón Rodríguez J, López-Fernández LA, and Lucendo AJ

Subjects
Humans, Adult, Infliximab therapeutic use, Polymorphism, Single Nucleotide genetics, Gastrointestinal Agents therapeutic use, Cross-Sectional Studies, Treatment Outcome, ADAM17 Protein genetics, Receptors, Interleukin genetics, Receptors, Interleukin therapeutic use, Crohn Disease drug therapy, Crohn Disease genetics
Abstract

Background: To predict primary failure of infliximab (IFX) therapy in Crohn's disease (CD) and to identify patients who maintain long-term effectiveness to IFX is currently not feasible. Some genetic variations are proposed as potential biomarkers., Aim: We assessed a set of single nucleotide polymorphisms (SNPs) in genes related to the IFX mechanism of action and the presence of HLA-DQA1 * 05 allele on the primary response and long-term durability in CD patients., Methods: A multi-centre cross-sectional study of IFX-exposed adult patients with CD was undertaken. Treatment persistence and time to failure were co-primary endpoints. DNA from the 131 patients was genotyped. Association between SNPs and clinical variables with IFX persistence was assessed., Results: Failure to IFX was documented in 65 (49.6%) out of 131 patients. IFX persistence was associated either with carrying the TT genotype in ADAM17 rs10929587 (ORa=0.2; 95%CI=0.1-0.8; p = 0.021), or the CC genotype in SLCO1C1 rs3794271 (ORa=0.2; 95%CI=0.1-0.7; p = 0.008), according to multivariate logistic regression. In contrast, previous bowel resection increased the risk of IFX failure (ORa=2.8; 95%CI=1.1-7.3; p = 0.025). Cox regression analysis confirmed these findings and also identified IL23R rs10489629-TT (HRa 0.41; 95%CI=0.22-0.75; p = 0.004) and concomitant immunosuppressants (HRa 0.46; 95%CI=0.27-0.77; p = 0.003) as protection from IFX failure. However, no association between HLA-DQA1 * 05 allele and persistence of IFX therapy was found, with similar failure rates among carriers and non-carriers (52.8% vs. 47.4%, respectively; p = 0.544)., Conclusions: SNPs rs10929587-TT in ADAM17, rs10489629-TT in IL23R and rs3794271-CC in SLCO1C1, together with no previous bowel surgery and concomitant immunosuppression, were identified as protection from failure to IFX., Competing Interests: Conflict of interest statement The authors have no conflict of interest., (Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results